Regulation of transporters by nuclear hormone receptors: Implications during inflammation

被引:53
作者
Teng, Shirley [1 ]
Piquette-Miller, Micheline [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada
关键词
drug transporters; inflammation; cytokines; nuclear receptors; PXR;
D O I
10.1021/mp700102q
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Membrane transporters play a critical role in the absorption, distribution, and elimination of both endogenous substrates and xenobiotics. Defects in transporter function can lead to altered drug disposition including toxicity or loss of efficacy. Inflammation is one condition during which variable drug response has been demonstrated, and this can be attributed, at least in part, to changes in the expression of transporter genes. Thus, knowledge of the mechanisms behind transporter regulation can significantly contribute to our ability to predict variations in drug disposition among individuals and during inflammatory disease. The discovery of several xenobiotic-activated nuclear hormone receptors during the past decade including the pregnane X receptor, constitutive androstane receptor, and farnesoid X receptor has contributed greatly toward this endeavor. These receptors regulate the expression of transporters such as P-glycoprotein, MRP2, MRP3, BCRP, and OATP2 (Oatp1a1/OATP1B1), all of which undergo altered expression during an inflammatory response. Nuclear receptors may therefore play an important role in mediating this effect. This review presents what is currently known about the role of nuclear receptors in transporter regulation during inflammation. The use of this knowledge toward understanding interindividual variation in drug response and drug interactions during inflammation as well toward the development of therapeutics to treat transporter-related diseases will also be discussed.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 103 条
[61]  
MOFFIT JS, 2006, J PHARM EXP THER
[62]   Down-regulation of intestinal drug transporters in chronic renal failure in rats [J].
Naud, Judith ;
Michaud, Josee ;
Boisvert, Caroline ;
Desbiens, Karine ;
Leblond, Francois A. ;
Mitchell, Andrew ;
Jones, Christine ;
Bonnardeaux, Alain ;
Pichette, Vincent .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 320 (03) :978-985
[63]   Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease [J].
Oostenbrug, Liekele E. ;
Dijkstra, Gerard ;
Nolte, Ilja M. ;
van Dullemen, Hendrik M. ;
Oosterom, Elvira ;
Faber, Klaas N. ;
de Jong, Dirk J. ;
van der Linde, Klaas ;
Meerman, Gerard J. Te ;
van der Steege, Gerrit ;
Kleibeuker, Jan H. ;
Jansen, Peter L. M. .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (10) :1174-1182
[64]  
Owen A, 2004, ANTIVIR THER, V9, P819
[65]  
Panwala CM, 1998, J IMMUNOL, V161, P5733
[66]   Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes:: Synergistic increase of CYP3A4 induction by pregnane X receptor activators [J].
Pascussi, JM ;
Drocourt, L ;
Fabre, JM ;
Maurel, P ;
Vilarem, MJ .
MOLECULAR PHARMACOLOGY, 2000, 58 (02) :361-372
[67]   Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes [J].
Pascussi, JM ;
Gerbal-Chaloin, S ;
Pichard-Garcia, L ;
Daujat, M ;
Fabre, JM ;
Maurel, P ;
Vilarem, MJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 274 (03) :707-713
[68]   Regulation of drug transporters during infections and inflammation [J].
Petrovic, Vanja ;
Teng, Shirley ;
Piquette-Miller, Micheline .
MOLECULAR INTERVENTIONS, 2007, 7 (02) :99-111
[69]  
PHETERSON AD, 1986, INT J PSYCHIAT MED, V16, P257
[70]   Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation [J].
Piquette-Miller, M ;
Pak, A ;
Kim, H ;
Anari, R ;
Shahzamani, A .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :706-711